Loading...

Bayer CropScience

BSE:506285
Snowflake Description

Excellent balance sheet with reasonable growth potential and pays a dividend.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
506285
BSE
₹140B
Market Cap
  1. Home
  2. IN
  3. Materials
Company description

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products in India. The last earnings update was 107 days ago. More info.


Add to Portfolio Compare Print
506285 Share Price and Events
7 Day Returns
-0.7%
BSE:506285
4%
IN Chemicals
3.5%
IN Market
1 Year Returns
-9.8%
BSE:506285
-0.9%
IN Chemicals
-0.9%
IN Market
506285 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bayer CropScience (506285) -0.7% -3% -5.1% -9.8% 5.5% 176.1%
IN Chemicals 4% -3% 7.2% -0.9% 56.2% 163.8%
IN Market 3.5% -2.6% 7.2% -0.9% 37.9% 44%
1 Year Return vs Industry and Market
  • 506285 underperformed the Chemicals industry which returned -0.9% over the past year.
  • 506285 underperformed the Market in India which returned -0.9% over the past year.
Price Volatility
506285
Industry
5yr Volatility vs Market
Related Companies

506285 Value

 Is Bayer CropScience undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Bayer CropScience to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Bayer CropScience.

BSE:506285 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 15.4%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BSE:506285
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Chemicals Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.871 (1 + (1- 35%) (1.23%))
0.918
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.92
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.918 * 8.6%)
15.45%

Discounted Cash Flow Calculation for BSE:506285 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Bayer CropScience is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

BSE:506285 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 15.45%)
2019 998.00 Analyst x1 864.47
2020 2,288.67 Analyst x3 1,717.19
2021 3,173.75 Analyst x4 2,062.65
2022 3,367.75 Est @ 6.11% 1,895.87
2023 3,588.12 Est @ 6.54% 1,749.67
2024 3,833.75 Est @ 6.85% 1,619.31
2025 4,104.30 Est @ 7.06% 1,501.63
2026 4,400.01 Est @ 7.2% 1,394.42
2027 4,721.58 Est @ 7.31% 1,296.12
2028 5,070.07 Est @ 7.38% 1,205.56
Present value of next 10 years cash flows ₹15,306.89
BSE:506285 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ₹5,070.07 × (1 + 7.55%) ÷ (15.45% – 7.55%)
₹69,050.34
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹69,050.34 ÷ (1 + 15.45%)10
₹16,418.81
BSE:506285 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹15,306.89 + ₹16,418.81
₹31,725.69
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹31,725.69 / 34.33
₹924.04
BSE:506285 Discount to Share Price
Calculation Result
Value per share (INR) From above. ₹924.04
Current discount Discount to share price of ₹4,056.90
= -1 x (₹4,056.90 - ₹924.04) / ₹924.04
-339%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Bayer CropScience is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bayer CropScience's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bayer CropScience's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BSE:506285 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in INR ₹88.68
BSE:506285 Share Price ** BSE (2019-05-22) in INR ₹4056.9
India Chemicals Industry PE Ratio Median Figure of 232 Publicly-Listed Chemicals Companies 14.76x
India Market PE Ratio Median Figure of 2,756 Publicly-Listed Companies 15.41x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bayer CropScience.

BSE:506285 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:506285 Share Price ÷ EPS (both in INR)

= 4056.9 ÷ 88.68

45.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bayer CropScience is overvalued based on earnings compared to the IN Chemicals industry average.
  • Bayer CropScience is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does Bayer CropScience's expected growth come at a high price?
Raw Data
BSE:506285 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 45.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
23.9%per year
India Chemicals Industry PEG Ratio Median Figure of 53 Publicly-Listed Chemicals Companies 1.28x
India Market PEG Ratio Median Figure of 559 Publicly-Listed Companies 1.29x

*Line of best fit is calculated by linear regression .

BSE:506285 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 45.75x ÷ 23.9%

1.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bayer CropScience is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Bayer CropScience's assets?
Raw Data
BSE:506285 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in INR ₹570.54
BSE:506285 Share Price * BSE (2019-05-22) in INR ₹4056.9
India Chemicals Industry PB Ratio Median Figure of 268 Publicly-Listed Chemicals Companies 1.42x
India Market PB Ratio Median Figure of 3,637 Publicly-Listed Companies 1.03x
BSE:506285 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:506285 Share Price ÷ Book Value per Share (both in INR)

= 4056.9 ÷ 570.54

7.11x

* Primary Listing of Bayer CropScience.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bayer CropScience is overvalued based on assets compared to the IN Chemicals industry average.
X
Value checks
We assess Bayer CropScience's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check)
  5. Bayer CropScience has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

506285 Future Performance

 How is Bayer CropScience expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bayer CropScience expected to grow at an attractive rate?
  • Bayer CropScience's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Bayer CropScience's earnings growth is expected to exceed the India market average.
  • Bayer CropScience's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
Raw Data
BSE:506285 Future Growth Rates Data Sources
Data Point Source Value (per year)
BSE:506285 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 23.9%
BSE:506285 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 13.4%
India Chemicals Industry Earnings Growth Rate Market Cap Weighted Average 18.8%
India Chemicals Industry Revenue Growth Rate Market Cap Weighted Average 13.6%
India Market Earnings Growth Rate Market Cap Weighted Average 17.1%
India Market Revenue Growth Rate Market Cap Weighted Average 10.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BSE:506285 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BSE:506285 Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 57,830 1
2023-03-31 50,287 1
2022-03-31 43,728 1
2021-03-31 37,263 3,845 4,978 5
2020-03-31 33,040 2,817 3,639 6
2019-03-31 28,806 1,553 3,137 5
BSE:506285 Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-12-31 28,639 3,045
2018-09-30 27,226 2,877
2018-06-30 28,505 3,356
2018-03-31 27,167 1,214 3,001
2017-12-31 26,375 2,769
2017-09-30 28,203 3,030
2017-06-30 26,796 2,715
2017-03-31 28,153 1,573 2,910
2016-12-31 40,105 3,323
2016-09-30 32,030 3,342
2016-06-30 38,027 3,215
2016-03-31 27,838 2,065 3,151

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Bayer CropScience's earnings are expected to grow significantly at over 20% yearly.
  • Bayer CropScience's revenue is expected to grow by 13.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BSE:506285 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Bayer CropScience Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:506285 Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31
2021-03-31 129.99 166.30 99.40 5.00
2020-03-31 103.28 114.00 88.50 5.00
2019-03-31 91.29 94.00 90.30 5.00
BSE:506285 Past Financials Data
Date (Data in INR Millions) EPS *
2018-12-31 88.68
2018-09-30 83.79
2018-06-30 97.06
2018-03-31 86.16
2017-12-31 78.92
2017-09-30 85.74
2017-06-30 76.79
2017-03-31 82.31
2016-12-31 93.98
2016-09-30 94.29
2016-06-30 89.91
2016-03-31 87.34

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Bayer CropScience is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Bayer CropScience's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bayer CropScience has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

506285 Past Performance

  How has Bayer CropScience performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bayer CropScience's growth in the last year to its industry (Chemicals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bayer CropScience's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Bayer CropScience's 1-year earnings growth exceeds its 5-year average (10% vs -3.3%)
  • Bayer CropScience's earnings growth has not exceeded the IN Chemicals industry average in the past year (10% vs 13.1%).
Earnings and Revenue History
Bayer CropScience's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bayer CropScience Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:506285 Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 28,639.00 3,045.00 4,621.00
2018-09-30 27,226.00 2,877.00 4,476.00
2018-06-30 28,505.00 3,356.00 4,392.00
2018-03-31 27,167.00 3,001.00 4,328.00
2017-12-31 26,375.00 2,769.00 4,280.00
2017-09-30 28,203.00 3,030.00 4,242.00
2017-06-30 26,796.00 2,715.00 2,507.00
2017-03-31 28,153.00 2,910.00 4,129.00
2016-12-31 40,105.00 3,323.00 4,219.00
2016-09-30 32,030.00 3,342.00 3,519.00
2016-06-30 38,027.00 3,215.00 4,116.00
2016-03-31 27,838.00 3,151.00 4,073.00
2015-12-31 37,919.00 3,278.00 6,458.00
2015-09-30 38,569.00 3,554.00 6,469.00
2015-06-30 39,222.00 3,814.00 6,433.00
2015-03-31 37,233.00 3,830.00 3,994.00
2014-12-31 36,996.00 3,858.00 6,335.00
2014-09-30 36,390.00 3,698.00 6,347.00
2014-06-30 34,513.00 3,102.00 2,146.00
2014-03-31 32,452.00 2,895.00 6,223.00
2013-12-31 30,870.00 3,151.00 5,445.00
2013-09-30 30,195.00 11,794.00 5,348.00
2013-06-30 27,922.00 11,608.00 1,884.00
2013-03-31 27,253.00 11,617.00 5,244.00
2012-12-31 25,649.00 10,683.00 4,768.00
2012-09-30 25,158.90 1,916.60 4,673.30
2012-06-30 23,984.50 1,778.50 1,613.80

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Bayer CropScience has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Bayer CropScience used its assets more efficiently than the IN Chemicals industry average last year based on Return on Assets.
  • Bayer CropScience has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Bayer CropScience's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bayer CropScience has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

506285 Health

 How is Bayer CropScience's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bayer CropScience's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bayer CropScience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bayer CropScience's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bayer CropScience's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 14.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bayer CropScience Company Filings, last reported 4 months ago.

BSE:506285 Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 19,590.00 1,719.00 1,616.00
2018-09-30 19,590.00 1,719.00 1,616.00
2018-06-30 17,783.00 0.00 4,166.00
2018-03-31 17,783.00 0.00 4,166.00
2017-12-31 17,805.00 1,150.00 1,899.00
2017-09-30 17,805.00 1,150.00 1,899.00
2017-06-30 20,567.00 0.00 9,875.00
2017-03-31 20,567.00 0.00 8,877.00
2016-12-31
2016-09-30
2016-06-30 17,559.00 0.00 7,996.00
2016-03-31 18,394.00 0.00 7,996.00
2015-12-31 22,903.00 0.00 6,542.00
2015-09-30 22,903.00 0.00 6,542.00
2015-06-30 20,329.00 0.00 11,558.00
2015-03-31 20,329.00 0.00 11,558.00
2014-12-31 20,098.00 0.00 3,078.00
2014-09-30 20,098.00 0.00 3,078.00
2014-06-30 17,423.00 0.00 4,865.00
2014-03-31 17,423.00 0.00 4,865.00
2013-12-31 21,356.00 0.00 9,655.00
2013-09-30 21,356.00 0.00 9,655.00
2013-06-30 19,313.00 0.00 9,741.00
2013-03-31 19,313.00 0.00 9,741.00
2012-12-31
2012-09-30
2012-06-30
  • Bayer CropScience's level of debt (8.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 8.8% today).
  • Debt is well covered by operating cash flow (70.6%, greater than 20% of total debt).
  • Bayer CropScience earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Bayer CropScience's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bayer CropScience has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

506285 Dividends

 What is Bayer CropScience's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.44%
Current annual income from Bayer CropScience dividends. Estimated to be 0.56% next year.
If you bought ₹2,000 of Bayer CropScience shares you are expected to receive ₹9 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Bayer CropScience's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.54%).
  • Bayer CropScience's dividend is below the markets top 25% of dividend payers in India (2.03%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BSE:506285 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
India Chemicals Industry Average Dividend Yield Market Cap Weighted Average of 164 Stocks 1%
India Market Average Dividend Yield Market Cap Weighted Average of 1407 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BSE:506285 Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31
2021-03-31 24.45 4.00
2020-03-31 21.62 5.00
2019-03-31 17.75 2.00
BSE:506285 Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2018-07-17 18.000 0.425
2017-08-28 17.000 0.403
2017-05-24 17.000 0.375
2016-08-03 17.000 0.413
2015-05-27 21.000 0.570
2015-02-02 8.000 0.227
2014-09-17 8.000 0.289
2014-08-05 5.500 0.236
2014-05-30 5.500 0.302
2013-08-05 5.000 0.320
2013-05-20 5.000 0.348
2012-08-07 4.200 0.375
2012-06-01 4.200 0.509
2011-05-23 4.000 0.495
2010-05-28 4.000 0.450
2009-06-30 2.800 0.607

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Bayer CropScience's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (4.9x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (5.2x coverage).
X
Income/ dividend checks
We assess Bayer CropScience's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bayer CropScience afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bayer CropScience has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

506285 Management

 What is the CEO of Bayer CropScience's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Duraiswami Narain
AGE 55
TENURE AS CEO 0.4 years
CEO Bio

Mr. Duraiswami Narain has been Vice Chairman & Managing Director and CEO of Bayer CropScience Limited since December 1, 2018 and its Director since October 23, 2018. Mr. Narain served as Vice President and Treasurer at Monsanto Company from October 2015 to June 7, 2018. Mr. Narain led the Treasury function (Financing, Cash Management, Insurance, Credit, Foreign Currency and Commodity Risk, Pension and 401K) at Monsanto Company. He served as an EMEA Regional Finance Lead at Monsanto Company and also served as its India Regional Business Lead from July 2010 to February 2013, International Finance Lead from March 2013 to August 2014 and Assistant Treasurer from September 2014 to October 2015. Mr. Narain holds a Bachelor’s Degree in Commerce from University of Madras, Chennai, India and MBA from Kellogg School of Management, Northwestern University. He is a Chartered Accountant.

CEO Compensation
  • Insufficient data for Duraiswami to compare compensation growth.
  • Insufficient data for Duraiswami to establish whether their remuneration is reasonable compared to companies of similar size in India.
Management Team Tenure

Average tenure and age of the Bayer CropScience management team in years:

3.9
Average Tenure
56
Average Age
  • The tenure for the Bayer CropScience management team is about average.
Management Team

Ulrich Stefer

TITLE
CFO & Executive Director
COMPENSATION
₹45M
AGE
49
TENURE
3.1 yrs

Rajiv Wani

TITLE
Head of Law
COMPENSATION
₹13M
AGE
59
TENURE
6.5 yrs

Duraiswami Narain

TITLE
Vice Chairman
AGE
55
TENURE
0.4 yrs

Anil Jain

TITLE
VP of Marketing & Co-operations
COMPENSATION
₹4M
AGE
62

Ajit Sawant

TITLE
Head of Manufacturing
COMPENSATION
₹3M
AGE
72

Bernd Lohmann

TITLE
Head of BBS AP ODC
COMPENSATION
₹23M
AGE
50

Mathias Kremer

TITLE
Head of Strategy & Portfolio Management
AGE
56
TENURE
3.9 yrs

Joerg Rehbein

TITLE
Head of Bayer CropScience

Pravin Trama

TITLE
General Manager of Zonal Accounts
COMPENSATION
₹3M
AGE
48

Asif Tanweer

TITLE
General Manager of Business Development & Stewardship
COMPENSATION
₹3M
AGE
62
TENURE
34.6 yrs
Board of Directors Tenure

Average tenure and age of the Bayer CropScience board of directors in years:

1.6
Average Tenure
54.5
Average Age
  • The average tenure for the Bayer CropScience board of directors is less than 3 years, this suggests a new board.
Board of Directors

Pankaj Patel

TITLE
Chairman of the Board
COMPENSATION
₹1M
AGE
65
TENURE
2.8 yrs

Ulrich Stefer

TITLE
CFO & Executive Director
COMPENSATION
₹45M
AGE
49
TENURE
3.2 yrs

Duraiswami Narain

TITLE
Vice Chairman
AGE
55
TENURE
0.4 yrs

Jens Hartmann

TITLE
Non-Executive & Non-Independent Director
COMPENSATION
₹19M
AGE
52
TENURE
0.3 yrs

Peter Mueller

TITLE
Non-Executive Non-Independent Director
AGE
58
TENURE
7.8 yrs

Ketaki Bhagwati

TITLE
Independent Woman Director
AGE
54
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Bayer CropScience's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bayer CropScience has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

506285 News

Simply Wall St News

What Should You Know About Bayer CropScience Limited's (BOM:506285) Growth?

After Bayer CropScience Limited's (BOM:506285) earnings announcement in March 2018,. … With net income at current levels of ₹3.00b, we should see this rise to ₹3.62b in 2019 … Below is a brief commentary on the longer term outlook the market has for Bayer CropScience

Simply Wall St -

Top BSE High Growth Stock

506285’s projected future profit growth is a robust 20.19%, with an underlying 53.25% growth from its revenues expected over the upcoming years. … BSE:506285 Future Profit Mar 13th 18 Havells India Limited (BSE:517354) Havells India Limited manufactures and sells industrial and consumer electrical products in India and internationally. … BSE:517354 Future Profit Mar 13th 18 Symphony Limited (BSE:517385) Symphony Limited engages in the manufacturing and trading of residential, commercial, and industrial air coolers in India and internationally.

Simply Wall St -

506285 Company Info

Description

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products in India. It also provides pharmaceutical products, such as prescription products primarily for cardiology and women’s healthcare; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and contrast-enhanced diagnostic imaging equipment and other contrast agents. In addition, the company offers consumer health products that primarily comprise non-prescription products for the dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection, and cardiovascular risk prevention areas under the Claritin, Aspirin, Aleve, Bepanthen/Bepanthol, Canesten, Dr. Scholl’s, and Coppertone brand names. Further, it provides animal health products for farm animals and companion animals, as well as involved in the sale and distribution of hybrid seeds. The company also exports its products. Bayer CropScience Limited was incorporated in 1958 and is based in Thane, India.

Details
Name: Bayer CropScience Limited
506285
Exchange: BSE
Founded: 1958
₹139,528,288,592
34,333,593
Website: http://www.bayer.in
Address: Bayer CropScience Limited
Bayer House,
Central Avenue,
Thane,
Maharashtra, 400076,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 506285 Equity Shares Mumbai Stock Exchange IN INR 10. Jul 2001
NSEI BAYERCROP Equity Shares National Stock Exchange of India IN INR 10. Jul 2001
Number of employees
Current staff
Staff numbers
1,148
Bayer CropScience employees.
Industry
Fertilizers and Agricultural Chemicals
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 12:42
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/05/18
Last earnings filing: 2019/02/04
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.